Literature DB >> 31537918

Mechanisms of sacubitril-valsartan benefit in HFrEF.

Irene Fernández-Ruiz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31537918     DOI： 10.1038/s41569-019-0282-2

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction.

Authors:  James L Januzzi; Margaret F Prescott; Javed Butler; G Michael Felker; Alan S Maisel; Kevin McCague; Alexander Camacho; Ileana L Piña; Ricardo A Rocha; Amil M Shah; Kristin M Williamson; Scott D Solomon
Journal:  JAMA       Date:  2019-09-17       Impact factor: 56.272

2.  Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

Authors:  Akshay S Desai; Scott D Solomon; Amil M Shah; Brian L Claggett; James C Fang; Joseph Izzo; Kevin McCague; Cheryl A Abbas; Ricardo Rocha; Gary F Mitchell
Journal:  JAMA       Date:  2019-09-17       Impact factor: 56.272
  2 in total
  1 in total

Review 1.  Cardiac natriuretic peptides.

Authors:  Jens P Goetze; Benoit G Bruneau; Hugo R Ramos; Tsuneo Ogawa; Mercedes Kuroski de Bold; Adolfo J de Bold
Journal:  Nat Rev Cardiol       Date:  2020-05-22       Impact factor: 32.419
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.